share_log

bluebird bio | 8-K: bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance

bluebird bio | 8-K: Current report

bluebird bio | 8-K:重大事件
SEC announcement ·  03/26 07:09
Moomoo AI 已提取核心信息
On March 26, 2024, bluebird bio, Inc. disclosed its financial results for the fourth quarter and the full year ended December 31, 2023, and provided updates on its operational progress and guidance for 2024. The company reported a full year 2023 revenue of $29.5 million, with $7.8 million generated in the fourth quarter. bluebird bio also announced a $175 million term loan facility with Hercules Capital, which is expected to extend the company's cash runway through Q1 2026. The company has seen 9 patient starts in 2024 for its gene therapies ZYNTEGLO and SKYSONA, and anticipates 85 to 105 patient starts across its portfolio in 2024. A government outcomes-based agreement for sickle cell disease was signed with Michigan Medicaid, and 62 qualified treatment centers have been activated. However, bluebird bio also announced that it will...Show More
On March 26, 2024, bluebird bio, Inc. disclosed its financial results for the fourth quarter and the full year ended December 31, 2023, and provided updates on its operational progress and guidance for 2024. The company reported a full year 2023 revenue of $29.5 million, with $7.8 million generated in the fourth quarter. bluebird bio also announced a $175 million term loan facility with Hercules Capital, which is expected to extend the company's cash runway through Q1 2026. The company has seen 9 patient starts in 2024 for its gene therapies ZYNTEGLO and SKYSONA, and anticipates 85 to 105 patient starts across its portfolio in 2024. A government outcomes-based agreement for sickle cell disease was signed with Michigan Medicaid, and 62 qualified treatment centers have been activated. However, bluebird bio also announced that it will restate its consolidated financial statements for 2022 and for the first three quarters of both 2022 and 2023 due to accounting errors related to lease agreements with contract manufacturers. The restatement is expected to result in an increase in lease assets and lease liabilities, as well as an increase in non-cash interest expense, but will not impact the company's cash position or revenue. The company plans to file its restated 2023 Form 10-K by April 16, 2024.
2024年3月26日,蓝鸟生物公司披露了截至2023年12月31日的第四季度和全年财务业绩,并提供了其2024年的最新运营进展和指导。该公司报告称,2023年全年收入为2950万美元,第四季度收入为780万美元。蓝鸟生物还宣布向Hercules Capital提供1.75亿美元的定期贷款,预计该公司的现金流将延长至2026年第一季度。该公司的基因疗法ZYNTEGLO和SKYSONA在2024年有9名患者开始接受治疗,预计到2024年,其产品组合中将有85至105名患者开始接受治疗。与密歇根州医疗补助计划签署了一项以政府结果为基础的镰状细胞病协议,并启动了62个合格的治疗中心。但是,蓝鸟生物还宣...展开全部
2024年3月26日,蓝鸟生物公司披露了截至2023年12月31日的第四季度和全年财务业绩,并提供了其2024年的最新运营进展和指导。该公司报告称,2023年全年收入为2950万美元,第四季度收入为780万美元。蓝鸟生物还宣布向Hercules Capital提供1.75亿美元的定期贷款,预计该公司的现金流将延长至2026年第一季度。该公司的基因疗法ZYNTEGLO和SKYSONA在2024年有9名患者开始接受治疗,预计到2024年,其产品组合中将有85至105名患者开始接受治疗。与密歇根州医疗补助计划签署了一项以政府结果为基础的镰状细胞病协议,并启动了62个合格的治疗中心。但是,蓝鸟生物还宣布,由于与合同制造商的租赁协议有关的会计错误,它将重报其2022年以及2022年和2023年前三个季度的合并财务报表。重报预计将导致租赁资产和租赁负债增加,以及非现金利息支出的增加,但不会影响公司的现金状况或收入。该公司计划在2024年4月16日之前提交其重报的2023年10-K表格。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息